START

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia

Retrieved on: 
torsdag, maj 30, 2024
CDER, New Drug Application, Patient, Pharmacokinetics, FA, NDA, START, FDA, OLE, Therapy, Chemistry, Disease, Safety, LRMR, Mitochondrion, CMC, Interim, Communication, BLA, Ataxia, Support, Pharmaceutical industry

BALA CYNWYD, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the United States Food and Drug Administration (FDA) has selected nomlabofusp to participate in the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program.

Key Points: 
  • BALA CYNWYD, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the United States Food and Drug Administration (FDA) has selected nomlabofusp to participate in the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program.
  • Nomlabofusp is a novel protein replacement therapy designed to address the root cause of Friedreich’s ataxia (FA) by delivering frataxin to mitochondria.
  • “We are thrilled nomlabofusp, the first potential therapy to increase frataxin levels in patients with FA, has been selected by the FDA to participate in the START pilot program.
  • “We look forward to participating in this pilot program and working with the FDA to further the development of nomlabofusp which has the potential to address the root cause of Friedreich’s Ataxia by increasing frataxin levels.”
    Dr. Russell Clayton, Chief Medical Officer of Larimar added, “Participating in the START program enables increased communication with the FDA to help expedite the progression of our nomlabofusp development program to the pre-BLA meeting stage.

Northwell Health and The START Center for Cancer Research to Form Strategic Partnership, Increasing Patient Access to Breakthrough Cancer Research

Retrieved on: 
fredag, maj 31, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Partnership, Patient, Running, Principal investigator, Hope, START, MD, Third Avenue, Physician, Cancer, Pharmaceutical industry

A new START early-phase clinical trial site is to be established at the Zuckerberg Cancer Center, part of Northwell Health’s Cancer Institute .

Key Points: 
  • A new START early-phase clinical trial site is to be established at the Zuckerberg Cancer Center, part of Northwell Health’s Cancer Institute .
  • A second START clinical trial site is planned for the Goldman Health Care Pavilion on Third Avenue between 76th and 77th streets in Manhattan.
  • Slated to open in 2026, this outpatient facility, led by the Northwell Health Cancer Institute, will offer innovative cancer care programs for various cancer types and will also provide access to Northwell's cutting-edge cancer research and clinical trials.
  • START's expanded site network offers a strategic advantage in navigating the challenges commonly faced in early-phase cancer research.

Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease

Retrieved on: 
måndag, april 22, 2024
Amyloid, Alzheimer's disease, Jort, University, MCI, Inflammation, Oxidative stress, ARIA, News, Research, Neuroinflammation, Cognition, Doctor of Philosophy, ADAS, START, KOL, Patient, SHINE, Perception, Neuron, Antibody, Therapy, Plaque, Cerebrospinal fluid

“The KOL roundtable we conducted featured a panel of Alzheimer’s disease expert clinicians and researchers who highlighted the need to find Alzheimer’s disease treatments that are less burdensome for patients and their care partners,” said Lisa Ricciardi, Cognition’s president and CEO .

Key Points: 
  • “The KOL roundtable we conducted featured a panel of Alzheimer’s disease expert clinicians and researchers who highlighted the need to find Alzheimer’s disease treatments that are less burdensome for patients and their care partners,” said Lisa Ricciardi, Cognition’s president and CEO .
  • The SHINE study enrolled participants in the U.S. and several countries in Europe including The Netherlands.
  • Dr. Vijverberg reviewed the design of the SHINE study and the results of the preliminary analysis of the first 24 patients who finished six months of treatment.
  • An archive of the KOL roundtable discussion is available on the News & Events page of the Investors section of the Cognition website or may be accessed directly at the following URL: https://lifescievents.com/event/cognition/ .

Ambassador Thomas Graham, Jr. Appointed As Chairman Emeritus of Lightbridge Corporation

Retrieved on: 
torsdag, april 18, 2024
President Clinton, Georgetown University, Stanford University, Harvard Law School, Nuclear energy, University, Safety, Annual general meeting, Book, Arms control, Princeton University, Comprehensive Nuclear-Test-Ban Treaty, History, START, American Bar Association, Special, LTBR, Nuclear

RESTON, Va., April 18, 2024 (GLOBE NEWSWIRE) -- Lightbridge Corporation (“Lightbridge”) (Nasdaq: LTBR), an advanced nuclear fuel technology company, today announced that Ambassador Thomas Graham, Jr. will be retiring as Executive Chairman and director of Lightbridge effective as of the upcoming Annual Meeting of Shareholders.

Key Points: 
  • RESTON, Va., April 18, 2024 (GLOBE NEWSWIRE) -- Lightbridge Corporation (“Lightbridge”) (Nasdaq: LTBR), an advanced nuclear fuel technology company, today announced that Ambassador Thomas Graham, Jr. will be retiring as Executive Chairman and director of Lightbridge effective as of the upcoming Annual Meeting of Shareholders.
  • Ambassador Graham has been appointed Chairman Emeritus.
  • “I am honored to accept the appointment as Chairman Emeritus of Lightbridge,” said Ambassador Graham.
  • As he transitions to the role of Chairman Emeritus, we look forward to continuing to benefit from his wisdom and guidance.

Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets

Retrieved on: 
tisdag, april 16, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Neurodegenerative disease, American Academy, TMC, Safety, Education, Teva, TEVA, MD, Doctor of Philosophy, START, HD, Psychiatry, Patient, AAN, Eating, Medication, Teva Pharmaceuticals, Chorea

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced final results from the HD cohort of the Phase 4 START study, demonstrating positive real-world effectiveness, safety, adherence and satisfaction with the 4-week Titration Kit for AUSTEDO.

Key Points: 
  • Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced final results from the HD cohort of the Phase 4 START study, demonstrating positive real-world effectiveness, safety, adherence and satisfaction with the 4-week Titration Kit for AUSTEDO.
  • As a fatal, neurodegenerative disease, HD can cause cognitive deterioration, behavioral and/or psychological problems and uncontrollable body movements known as chorea – a symptom that can have a significant impact on daily activities like eating or talking.3-5 These data are being presented at the 2024 American Academy of Neurology (AAN) Annual Meeting.
  • “90% of HD patients experience chorea,3,4 so it’s important for patients to have a treatment option that not only helps address symptoms, but helps provide a positive patient experience,” said Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer at Teva.
  • “I’m glad to see this outcome as it gives clinicians more confidence and patients more control.”

The START Center for Cancer Research Takes a Major Step Forward in its Mission to Bring the Hope of Cancer Research to Communities Globally

Retrieved on: 
måndag, april 8, 2024
Oncology, Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, ChromeOS, FJD, MBE, Growth, Environment, Patient, Pi, Cancer, EMA, MD, FRCPC, START, PDX, Clinical trial, Safety, Multimedia, Principal investigator, FDA, Physician, Pharmaceutical industry

The START Center for Cancer Research, the world's largest global site network of early phase oncology clinical trials, sets its sights on expanding access to breakthrough research to all communities globally.

Key Points: 
  • The START Center for Cancer Research, the world's largest global site network of early phase oncology clinical trials, sets its sights on expanding access to breakthrough research to all communities globally.
  • Slack, a respected leader in the clinical research industry, brings nearly 20 years of experience to grow START's mission of revolutionizing cancer clinical research.
  • With a global network spanning eight locations, including START San Antonio, START Midwest, START Mountain Region, START Madrid (FJD and CIOCC), START Barcelona, START Dublin, and START Lisbon, START is at the forefront of advancing cancer research.
  • Co-founders of The START Center for Cancer Research, Amita Patnaik, MD, FRCPC, and Kyriakos P. Papadopoulos, MD, will continue their pivotal roles as Co-directors of Clinical Research at START San Antonio.

Arieli Capital Launching 2nd Cohort of START Agri-Tech Scale-Up Program With 11 Cutting-Edge Ventures

Retrieved on: 
torsdag, april 4, 2024
Electricity, Pollination, Pesticide, Health, Utah Tech University, Organization, Farmer, Growth, Nutrient, Agriculture, Partnership, Agricultural technology, Climate, Food, Ramat HaNegev Regional Council, Energy, START, Carbon, Plant, Chemistry, Investment, Water, Haifa Group, Cosmetics, Soil, Eden, Drinking water, Medicine

The first cohort of the program included 8 ventures, who've collectively raised a combined $9.5M in investment capital and have made impressive milestones after participating.

Key Points: 
  • The first cohort of the program included 8 ventures, who've collectively raised a combined $9.5M in investment capital and have made impressive milestones after participating.
  • "Our first cohort showcased just how much value can be created through this program, and we knew from then that we'd return with another group."
  • We're thrilled to work alongside our Utah partners on this impactful program deepening Arieli's existing Utah activity and investments."
  • Arieli Capital invites the agri-tech and climate-tech community, as well as the broader high-tech ecosystem to take part at the final expo and pitch event, and follow for more updates here.

Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting

Retrieved on: 
onsdag, februari 28, 2024
Research, Clinical Trials, Biotechnology, Managed Care, Health, Cosmetics, Pharmaceutical, Retail, Science, Acne, Nemolizumab, Pacific Ocean, Atopic dermatitis, Prurigo nodularis, Hyperhidrosis, Dermatology, Skin, Consultant, AAD, Marriott Marquis, Safety, Patient, Itch, START, American Academy, Medical device

Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio.

Key Points: 
  • Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio.
  • “Our vast presence at AAD combines new data, novel educational activities and patient perspectives, demonstrating how we are putting our commitment to addressing the needs of the dermatology community into action.
  • The event is taking place on Saturday, March 9, in the Pacific Ballroom 21-26, Marriott Marquis San Diego Marina, from 7:00 to 9:00 PM PST.
  • *All presenters are paid consultants or employees of Galderma.

Arieli Capital Unveils START FashionTech in Milan, Merging Couture with Cutting-Edge Technology

Retrieved on: 
torsdag, februari 22, 2024
Head, Innovation, Ministry, AI, Growth, Intel Ignite, Milan Fashion Week, Fashion, Authentication, Medicine, Supply chain management, NFC, Agriculture, Microsoft, START, Partner, Cryptocurrency

Scheduled for March 4th-7th in Milan, Italy, soon after Milan Fashion Week, the program will connect FashionTech startups with prominent brands and investors, offering unique growth prospects in the fashion, retail and design industries.

Key Points: 
  • Scheduled for March 4th-7th in Milan, Italy, soon after Milan Fashion Week, the program will connect FashionTech startups with prominent brands and investors, offering unique growth prospects in the fashion, retail and design industries.
  • We're highly impressed by the advanced and creative ventures in the Fashion space," says Or Haviv, Partner and head of Innovation at Arieli.
  • Arieli's global programs have previously aided various Italian startups across industries such as agriculture, medicine, and climate establish strong business foundations, raise capital and enter new markets.
  • The global sustainable fashion market, valued at $7.8B in 2023, is expected to surpass $33B by 2030 with a remarkable CAGR of nearly 23%.

A New Era in Desert Technology: START AgriTech Program Launched in Utah, USA by Arieli Capital & Utah Tech University

Retrieved on: 
torsdag, december 21, 2023
Senate, Desert Tech, Partnership, Agriculture, Seed, Student, Utah Tech University, Agricultural technology, Climate change, Health, Innovation, Knowledge, Water, Food, START, Innovation Hub, Growth, Haifa Group, Potash

To address these, Arieli Capital LLC ("Arieli") together with Frontier RNG Agro-climate Innovation Hub, in collaboration with Utah Tech University and Haifa Group, are excited to open registration for the START AgriTech Program, taking place April 15-18, 2024, on the Utah Tech Campus in St George, Utah.

Key Points: 
  • To address these, Arieli Capital LLC ("Arieli") together with Frontier RNG Agro-climate Innovation Hub, in collaboration with Utah Tech University and Haifa Group, are excited to open registration for the START AgriTech Program, taking place April 15-18, 2024, on the Utah Tech Campus in St George, Utah.
  • Utah Tech and Arieli Capital's partnership is a pivotal opportunity for Desert Tech and AgriTech leaders in Utah, marking a significant stride in innovation and growth.
  • Utah Tech University President Richard "Biff" Williams, "The partnership between Utah Tech University and Arieli Capital marks an exciting collaboration, driving innovation and commercialization in AgTech and Desert Tech within the state, particularly in southwest Utah.
  • Arieli actively invests in desert and agriculture technologies alongside its innovation center, Frontier, located in the Israeli Negev desert.